Equine CXCL7 (C-X-C motif chemokine ligand 7), also known as NAP-2 (neutrophil-activating peptide 2) or PPBP (pro-platelet basic protein), is a platelet-derived chemokine belonging to the ELR⁺ CXC chemokine family, which includes CXCL1, CXCL2, CXCL3, and CXCL5 that regulate neutrophil recruitment during inflammatory responses. In horses (Equus caballus), CXCL7 is produced primarily by platelets and megakaryocytes and is released during platelet activation following vascular injury, inflammation, or infection. CXCL7 signals mainly through the chemokine receptor CXCR2, expressed on neutrophils and other innate immune cells, promoting neutrophil chemotaxis, activation, and migration to sites of tissue damage or infection. In equine health, CXCL7 contributes to the interaction between hemostasis and immune responses, particularly during inflammatory conditions affecting the vascular system, musculoskeletal tissues, and respiratory tract, where platelet activation and neutrophil recruitment support host defense and tissue repair. Horses are also used as comparative animal models for musculoskeletal and inflammatory diseases, and platelet-derived chemokines such as CXCL7 have been examined in equine models of tendon and ligament injury, where platelet-rich plasma (PRP) therapies release platelet chemokines that influence inflammation, leukocyte recruitment, and tissue regeneration, providing insight into platelet-mediated healing mechanisms relevant to both veterinary and human medicine.